Waiting for news AAPL, ACTC and Geron

Waiting on AAPL's, iPod mini on Oct. 23rd and earnings Oct 25th. I need a $35 run up for my calls to make money.................................................. ...................................................................................... ...................................................................................... Geron we need good news on the last four phase two trials. If the news is poor Geron is done as a company................................................................. ,............................................................................................................................................................................. ACTC more good news on trials, a partner, listing on the big broad.................... .................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

AAPL up Geron and ACTC down

AAPL closed up $5.06 at $640.91 on 18.2 million shares. The three month avg. volume is 15.6 million Hoping for blow numbers on Oct 25th. ................................................................................................................................................................................................................................................................................................................................................................... ACTC was down a little at 0.074 on 4.4 million shares. The three month avg. volume is 6.2 million shares. Need more good news................................................ ..................................................................................................................................................................................................................................................................... Geron down 3 cents at $1.37 on 707,267 shares. The three month avg. volume is 1.6 month shares. Need good news on the last 4 remaining trials................................................................................. ..................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

GE Healthcare exercises option to Geron's cellular assay patents

08 October 2012 GE Healthcare exercises option to Geron’s cellular assay patents Agreement covers intellectual property relating to stem cell-based technologies for drug discovery and predictive toxicity screening CHALFONT ST. GILES, UK – 8 October 2012 – GE Healthcare, the healthcare business of GE (NYSE: GE), announced today that it has expanded its 2009 license agreement with Geron Corporation for the development of cellular assays and models derived from embryonic stem cells (ESC’s) for use in drug discovery and toxicity screening. Under the terms of the expanded license, GE Healthcare obtains exclusive global rights to Geron’s intellectual property and know-how for the development and sale of cellular assays derived from induced pluripotent stem cells (iPS). Financial terms were not disclosed. GE Healthcare is pioneering the development of human cell-based assays and models for use in drug discovery and predictive toxicity screening. As the worldwide pharmaceutical industry seeks to reduce the cost of drug development and to bring more effective, safer drugs to market, the availability of more biologically relevant and predictive cell models is becoming increasingly important. In 2010 the company launched CytivaTM cardiomyocytes (human heart cells), stem cell-based assays that are already helping pharmaceutical companies develop safer medicines by identifying - much earlier in the discovery process - drug candidates that show toxic effects. The company also plans to launch Cytiva hepatocytes (liver cells) for toxicity testing, and recently announced a collaboration with the Beijing Genomic Institute aimed at understanding the underlying genetic variation between ethnically diverse stem cell lines.................................................................................. ....................................................................................... Dr Amr Abid, General Manager, Cell Technologies, GE Healthcare Life Sciences said, “Expanding our agreement with Geron is a significant step forward and will help us realise our vision of bringing the benefits of stem cell derived assays and models to pharmaceutical and cell science research. In the immediate term it will allow us to accelerate the development of new technologies and products for our customers in drug discovery. Longer term, by taking a licence from GE Healthcare, the wider industry will also benefit from the ability to use key intellectual property without violating patent rights. This clarity and freedom to operate will, I believe, do much to advance the use of stem cell based assays in drug discovery................................... This is great news and Geron is down, but I think this news slowed Geron drop. Also Geron filed a 8-K, which is a sales agreement between Geron and MLV & Co. for up to $50 million in shares. Still Geron closed down 5 cents at $1.41 on only 542,024 shares. The three month avg. volume is 1.6 million shares. ........................... AAPL closed down $2.32 at $635.85 on almost 30 million shares. The three month avg. volume is 15.7 million shares. I think we're done going down till earnings on the 25th. ...................................................................................... ACTC closed under 8 cents on 11.5 million shares. The three month avg. volume is 6.2 million shares. I don't know why this company is down the news the day before was good. ......................................................................................... Good luck in this rigged casino,

ACTC great news on Stargardt's disease trials

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company’s three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of second and third additional patients with Stargardt’s macular dystrophy (SMD) in the second patient cohort of its U.S. trial for the condition. Additionally, the DSMB has authorized the Company to treat all three patients in the second cohort of its European trial for SMD. The UK Medicines and Healthcare products Regulatory Agency (MHRA) recently approved a protocol modification to the DSMB review, streamlining the process, allowing the company to treat the first patient in a new cohort if the DSMB has allowed this in the US study, and once clearance has been received in the US trial to treat the next two patients in the US cohort. This would also allow for treatment of the UK patients without an additional review by the DSMB. Moreover, according to the protocol for both trials, each patient in the second cohort will be injected with 100,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells, up from 50,000 in the first cohort. “This authorization to treat the next five patients in the second, higher-dosage cohort in both our clinical trials for SMD represents a significant step forward for our clinical programs,” commented Gary Rabin, chairman and CEO of ACT. “We are also encouraged with the MHRA’s approval of the DSMB’s streamlined review process. Clearly this has the potential to help accelerate the pace of our European trial.” ACT is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration, SMD and dry age-related macular degeneration (dry AMD). Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format, from 50,000 hESC-derived RPE cells in the first patient cohort to 200,000 in the last and final cohort. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry-AMD or SMD at 12 months, the study’s primary endpoint. “We are eagerly anticipating treating these final two patients in the second cohort of our U.S. trial for SMD, and all three patients in the second cohort of our E.U. trial,” commented Robert Lanza, M.D., ACT’s chief scientific officer. “We are encouraged by the preliminary data in the first patient in this second, higher-dosage cohort and look forward to gathering more data.” Further information about patient eligibility for ACT’s SMD studies in the U.S. and E.U. as well as its dry AMD study are available at www.clinicaltrials.gov, with the following Identifiers: NCT01345006 (U.S. SMD), NCT01469832 (E.U. SMD), and NCT01344993 (dry AMD).........................................................................AAPL down again, so I bought 4 more shares. I need a $50 run for my calls to be above water. ..................................................................................... Good luck in this rigged casino,

AAPL, ACTC and Geron all down again

Bad Day at Black Rock, great movie, somes up Friday. .................................. .............................................................................................................................................................................. AAPL down $14.21 to close at $652.59 on 21.2 million shares. The three month avg. volume is 15.3 million shares. I bought and sold one AAPL call. I have 3 AAPL calls, two at Feb 2013 $685 and one at Feb 2013 $690. Need about $20+ run to made some money. .....................................................................................................................................................................................................................................................................ACTC closed down a little at 0.07 on 8 million shares. The three month avg. is 6 million shares. Need good news or we continue down..................................... ..................................................................................................................................................................................................................................................................... Geron down, down, down we go. Closed at $1.41. I'm thinking the big boys are running Geron down, then will run it back up before Dec 5th, when Geron tells us how the Phrase two trails are going. Just like they did before Geron give us the bad news on two of the Phase two trials. So if this happens will sell some and write a few covered calls.................................................................................................................................................................................................................................................................Good luck in this rigged casino,

ACTC, AAPL and GERON all down

Not good, all three stocks down on a up day............................................ .............................................................................................................................................................................. AAPL down $4.65 to close at $666.80 on 13.1 million shares. Bought a $685 Feb 2013 call and then sold it, made a little money. Then bought it back again at the end of the trading day. AAPL still is the best company out there............................. .............................................................................................................................................................................. ACTC down a little again at 0.0725 on 9.3 million shares. The 10 day avg. volume is 6.2 million shares. With no news we go lower........................................... .............................................................................................................................................................................. Geron closed down 3 cents at $1.59 on only 503,531 shares. The 10 day avg. is 1.2 million shares. With no news we go lower............................................... .............................................................................................................................................................................. Good luck in this rigged casino,

Geron and ACTC going nowhere

Geron down again to $1.62 on only 570,000 shares. The three month avg. volume is 1.6 million shares. No news, no interest............................................... .............................................................................................................................................................................. ACTC down again to 0.0727 on 5.5 million shares. The three month avg. volume is 6 million shares. Need news or we go lower.......................................... ..................................................................................................................................................................................................................................................................... AAPL up $10.14 to close at $671.45 on 15.1 million shares. The three month avg volume is 15.1 million shares. I bought two $690 call for Feb 2013, on Monday. Sold one today made $208 and will sell the 2nd this week I hope, need $7 more dollars. Earnings Oct 15th ................ ........................................................... ...................................................................................................................................................................... Good luck in this rigged casino,